Investors sentiment decreased to 1.36 in 2019 Q1. Its down 0.18, from 1.54 in 2018Q4. It is negative, as 9 investors sold Cytosorbents Corporation shares while 16 reduced holdings. 12 funds opened positions while 22 raised stakes. 8.04 million shares or 0.87% less from 8.11 million shares in 2018Q4 were reported.
Tower Research Capital (Trc) stated it has 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). Vanguard Gp stated it has 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). 98,228 were reported by Millennium Mngmt Lc. Ameritas Investment has 2,668 shares. Citigroup Incorporated accumulated 0% or 8,046 shares. Mycio Wealth Limited Liability Corporation accumulated 12,894 shares or 0.01% of the stock. Interest Group Inc holds 18,966 shares. Rhumbline Advisers invested in 42,589 shares or 0% of the stock. California State Teachers Retirement Systems accumulated 46,733 shares or 0% of the stock. State Common Retirement Fund invested in 0% or 31,600 shares. California-based California Employees Retirement has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). Skylands Ltd Limited Liability Company owns 636,050 shares. Renaissance Technologies Ltd Llc has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). Raymond James & Assocs holds 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO) for 168,800 shares. Creative Planning has invested 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO).
Analysts expect Cytosorbents Corporation (NASDAQ:CTSO) to report $-0.16 EPS on August, 1.They anticipate $0.03 EPS change or 15.79 % from last quarter’s $-0.19 EPS. After having $-0.15 EPS previously, Cytosorbents Corporation’s analysts see 6.67 % EPS growth. The stock increased 5.71% or $0.38 during the last trading session, reaching $7.03. About 111,561 shares traded. Cytosorbents Corporation (NASDAQ:CTSO) has declined 18.33% since July 15, 2018 and is downtrending. It has underperformed by 22.76% the S&P500.
Cytosorbents Corporation (NASDAQ:CTSO) Ratings Coverage
Among 3 analysts covering Cytosorbents Corp (NASDAQ:CTSO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cytosorbents Corp had 4 analyst reports since March 5, 2019 according to SRatingsIntel. FBR Capital maintained the stock with “Buy” rating in Tuesday, March 5 report. The firm earned “Buy” rating on Friday, March 8 by Maxim Group. On Friday, March 8 the stock rating was maintained by H.C. Wainwright with “Buy”.
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. The company has market cap of $226.71 million. The Company’s principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It currently has negative earnings. The firm also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
More notable recent Cytosorbents Corporation (NASDAQ:CTSO) news were published by: Prnewswire.com which released: “CytoSorbents Introduces the CytoSorb Therapeutic ECMOâ„¢ Kit at the 2017 European Society of Intensive Care Medicine Congress – PR Newswire” on September 26, 2017, also Prnewswire.com with their article: “CytoSorbents to Present at the Cowen 39th Annual Health Care Conference – PRNewswire” published on March 06, 2019, Finance.Yahoo.com published: “CytoSorbents to Participate at the B. Riley FBR 20th Annual Institutional Investor Conference – Yahoo Finance” on May 20, 2019. More interesting news about Cytosorbents Corporation (NASDAQ:CTSO) were released by: Prnewswire.com and their article: “CytoSorbents Highlights the 6th International CytoSorb Users’ Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences – PRNewswire” published on April 24, 2019 as well as Prnewswire.com‘s news article titled: “CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018 – PRNewswire” with publication date: March 07, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.